不同方案治疗人表皮生长因子受体2阳性乳腺癌患者的临床效果比较

Clinical efficacy of different therapeutic regimens for breast cancer patients with human epidermal growth factor receptor 2-positive:a comparative study

目的比较不同方案治疗人表皮生长因子受体2(HER2)阳性乳腺癌患者的临床效果。方法选取HER2阳性乳腺癌患者98例,按照随机数字表法分为A组32例、B组34例、C组32例。A组给予多西他赛、环磷酰胺及表阿霉素,B组给予曲妥珠单抗及卡铂治疗,C组给予紫杉醇、曲妥珠单抗及卡铂治疗,均治疗6个周期。比较3组患者客观有效率、临床获益率、HER2表达情况、中位生存期和不良反应发生情况。结果治疗后,C组的客观有效率、临床获益率高于A组和B组(P<0.05);B组、C组的HER2阴性率高于A组(P<0.05);A组、B组、C组的中位总生存期依次延长(P<0.05);3组患者的不良反应发生率比较,差异无统计学意义(P>0.05)。结论与单纯化疗药物比较,联合曲妥珠单抗靶向治疗HER2阳性乳腺癌患者疗效较好,可以显著提高患者生存期,且曲妥珠单抗联合紫杉醇治疗的效果更为明显。

Objective To compare the clinical efficacy among different therapeutic regimens for breast cancer patients with human epidermal growth factor receptor 2（ HER2）-positive. Methods A total of 98 patients with breast cancer were divided into group A（ 32 cases）,group B（ 34 cases） and group C（ 32 cases） using the random number table method. Group A was given docetaxel,cyclophosphamide and epirubicin,group B was treated with trastuzumab and carboplatin,and group C received paclitaxel,trastuzumab and carboplatin. The treatment lasted for 6 cycles in all groups. The objective response rate（ ORR）,clinical benefit rate（ CBR）,HER2 expression,median survival,and incidence of adverse reactions were compared among the three groups. Results After treatment,ORR and CBR in group C were higher than those in group A or B（ P〈0. 05）; the rate of HER2-negaive in group B or C was higher than that in group A（ P〈0. 05）;the median overall survival increased in sequence of group A 〈group B 〈group C（ P〈0. 05）; no statistically significant difference was found in the incidence rate of adverse reactions among the three groups（ P〈0. 05）. Conclusion Compared to chemotherapy drugs alone,targeted therapy combined with trastuzumab has favorable effects on breast cancer patients with HER2-positive and can significantly prolong survival time. Moreover,trastuzumab combine with docetaxel has better efficacy.